Innate Pharma (IPHYF) Stock Price, News & Analysis

Company Overview

Innate Pharma S.A. is a France-based biotechnology company focused on developing immunotherapies for cancer. The company’s research is centered on the innate immune system, including natural killer cells and other immune mechanisms that can recognize and attack tumor cells. Its activities include drug discovery, clinical development and collaborations with pharmaceutical companies.

Innate Pharma’s pipeline has included antibody-based therapies designed to stimulate or direct immune responses against cancer. Its lead investigational programs have included lacutamab, an antibody being developed for certain T-cell lymphomas, and other oncology candidates targeting immune checkpoints and tumor-associated pathways. The company has also advanced programs through strategic partnerships, including collaborations with AstraZeneca involving monalizumab and other immuno-oncology assets.

Founded in 1999 and headquartered in Marseille, France, Innate Pharma conducts research and development activities in Europe and works with international pharmaceutical partners to advance its therapies. The company’s leadership has included Chief Executive Officer Mondher Mahjoubi, who has guided its development as a clinical-stage immuno-oncology business. Innate Pharma’s shares trade in the United States under the symbol IPHYF.

Key Stats

• Today's Range: $1.65 to $1.65
• 50-Day Range: $1.65 to $1.65
• 52-Week Range: $1.37 to $2.25
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $138.32 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 9/23/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:IPHYF
• Previous Symbol: NASDAQ:IPHYF
• CIK: 1598599
• Web: www.innate-pharma.com
• Phone: (343) 030-3030
• Fax: 33-04-30-30-30-00
• Employees: 179
• Year Founded: 1999

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.27
• Quick Ratio: 1.27

Sales & Book Value

• Annual Sales: $10.19 million
• Price / Sales: 13.57
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.29) per share
• Price / Book: -5.69

Miscellaneous

• Outstanding Shares: 83,830,000
• Free Float: 57,097,000
• Market Cap: $138.32 million
• Optionable: Not Optionable
• Beta: 0.28